Jasper Therapeutics(US:JSPR) Prnewswire·2025-10-15 14:33Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by November 18, 2025 [1][3]. Company Overview - Jasper Therapeutics, Inc. is a publicly traded company on NASDAQ under the ticker JSPR [1]. - The company has faced significant challenges, including issues with third-party manufacturers and the integrity of clinical trial data [3][4]. Allegations and Issues - The complaint against Jasper alleges that the company lacked necessary controls to ensure compliance with current Good Manufacturing Practices (cGMP), which could confound clinical trial results [3]. - Specific concerns include the potential negative impact on the regulatory and commercial prospects of its product, briquilimab, and the likelihood of cost-reduction measures being implemented [3]. - Following a press release on July 7, 2025, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share due to the announcement of halted studies and restructuring plans [4]. Legal Proceedings - Investors who suffered losses between November 30, 2023, and July 3, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][5]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [2].